When the secondary efficacy analysis of mean change from baseline in FPG was assessed, it was found that patients receiving placebo showed a mean increase in FPG at all timepoints.
In contrast, for the ACTOS groups taking 15-, 30-, or 45-mg once-daily doses, there were statistically significant (P<=0.05) mean decreases from baseline at each visit.
At endpoint, the difference in FPG for the 45-mg/day group vs the placebo-treated group was 65.3 mg/dL.

Aronoff S, et al. Diabetes Care. 2000;23:1605-1611.